CytoSorbents Provides Update on CytoSorb and COVID-19 Coronavirus Activities

About this update from Cytosorbents Corporation

[{"type":"text","content":"MONMOUTH JUNCTION, N.J., March 12, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO) a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, provided an update from its Chief Executive Officer, Dr. Phillip Chan, MD, PhD.\n\n \n \n \n \n \n \n\n \nDr. Phillip Chan stated, \"As documented worldwide coronavirus cases surpass 125,000, we are witnessing a global escalation of activity to try to stem the tide of COVID-19 infection. The official World Health Organization (WHO) declaration of a formal pandemic, the lockdown on travel and non-essential businesses in Italy, and the U.S. ban on all travel from Europe, are just some examples. Coronavirus has also already begun to affect our own communities, with a shut down of schools, sporting events, conferences, and social gatherings. As testing in the U.S. becomes more available, the true extent of the spread of coronavirus will become clearer. \nIn discussions with physicians who are working in the epicenters of infection in Italy and China, the real problem with the COVID-19 pandemic is that serious and critically-ill patients are flooding hospitals, and overwhelming their ability to treat these patients. Intensive care units (ICU) are in gridlock and in many cases at the breaking point, as an increasing number of patients with life-threatening complications of COVID-19 infection such acute respiratory distress syndrome (ARDS), shock (i.e. a potentially fatal drop in blood pressure), kidney failure, acute cardiac injury and secondary bacterial infections, occupy the limited number of ICU beds, and consume tremendous medical, equipment, and healthcare worker resources, with little hope of a quick recovery and ICU discharge. \nThe underlying cause for these complications is often a cytokine storm that results in a massive, systemic inflammatory response, leading to the damage of vital organs such as the lungs, heart, and kidneys, and ultimately multiple organ failure and death in many cases. Steroids are being used reflexively to try to control this inflammation, despite WHO recommendations against using steroids in COVID-19 infection, and evidence from other coronavirus infections (e.g. SARS and MERS) and influenza that its use can delay vira...

More updates from Cytosorbents Corporation